MX2022007725A - Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo. - Google Patents
Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo.Info
- Publication number
- MX2022007725A MX2022007725A MX2022007725A MX2022007725A MX2022007725A MX 2022007725 A MX2022007725 A MX 2022007725A MX 2022007725 A MX2022007725 A MX 2022007725A MX 2022007725 A MX2022007725 A MX 2022007725A MX 2022007725 A MX2022007725 A MX 2022007725A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- cognitive impairment
- compositions
- containing gaba
- treating
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title abstract 9
- 208000028698 Cognitive impairment Diseases 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 title abstract 2
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 4
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 3
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 2
- 208000015114 central nervous system disease Diseases 0.000 abstract 2
- 229940126027 positive allosteric modulator Drugs 0.000 abstract 2
- 239000000018 receptor agonist Substances 0.000 abstract 2
- 229940044601 receptor agonist Drugs 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000000172 Medulloblastoma Diseases 0.000 abstract 1
- 208000036626 Mental retardation Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000006289 Rett Syndrome Diseases 0.000 abstract 1
- 230000007000 age related cognitive decline Effects 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 231100000867 compulsive behavior Toxicity 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta invención se refiere a derivados de benzodiazepinas, composiciones que comprenden cantidades terapéuticamente efectivas de esos derivados y métodos para usar esos derivados o composiciones en el tratamiento de deterioro cognitivo asociado con trastornos del CNS. También se refiere al uso de un agonista del receptor de GABAA que contiene a5 (por ejemplo, un modulador alostérico positivo para el receptor de GABAA que contiene a5) para tratar el deterioro cognitivo asociado con trastornos del CNS en un sujeto en necesidad o en riesgo de padecerlo, que incluye deterioro cognitivo relacionado con la edad, deterioro cognitivo leve (MCI), MCI amnésico, deterioro de la memoria asociado con la edad, disminución cognitiva relacionada con la edad, demencia, enfermedad de Alzheimer (AD), AD prodrómico, PTSD , esquizofrenia, trastorno bipolar, ALS, deterioro cognitivo relacionado con la terapia del cáncer, retraso mental, enfermedad de Parkinson, trastornos del espectro autista, trastorno X frágil, síndrome de Rett, comportamiento compulsivo y adicción a sustancias. También se refiere al uso de un agonista del receptor de GABAA que contiene a5 (por ejemplo, un modulador alostérico positivo del receptor de GABAA que contiene a5) en el tratamiento de cánceres cerebrales (que incluyen tumores cerebrales, por ejemplo, meduloblastomas) y deterioro cognitivo asociado con estos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950886P | 2019-12-19 | 2019-12-19 | |
| PCT/US2020/066182 WO2021127543A1 (en) | 2019-12-19 | 2020-12-18 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007725A true MX2022007725A (es) | 2022-07-19 |
Family
ID=76478828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007725A MX2022007725A (es) | 2019-12-19 | 2020-12-18 | Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230098667A1 (es) |
| EP (1) | EP4077333A4 (es) |
| JP (1) | JP2023507569A (es) |
| CN (1) | CN115175911A (es) |
| AU (1) | AU2020405233A1 (es) |
| IL (1) | IL294031A (es) |
| MX (1) | MX2022007725A (es) |
| WO (1) | WO2021127543A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020234880A1 (en) * | 2019-05-23 | 2020-11-26 | Life Guard Electrooptic Ltd. | System and a method for surveilling swimmers |
| WO2024023268A1 (en) | 2022-07-29 | 2024-02-01 | F. Hoffmann-La Roche Ag | Characterisation of neurological dysfunction |
| WO2024039886A1 (en) * | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112409363B (zh) * | 2013-12-20 | 2023-11-14 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法 |
| JP6987384B2 (ja) * | 2015-06-19 | 2021-12-22 | エージンバイオ， インコーポレイテッド | ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 |
| US20180170941A1 (en) * | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11414425B2 (en) * | 2018-06-19 | 2022-08-16 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| JP2023534189A (ja) * | 2020-07-10 | 2023-08-08 | エージンバイオ， インコーポレイテッド | Ｇａｂａａアルファ５アゴニストおよびｓｖ２ａ阻害剤の組合せ物ならびに認知障害の処置において使用する方法 |
| CA3185573A1 (en) * | 2020-07-10 | 2022-01-13 | Deepa GANDLA | Polymorphs of a gabaa .alpha.5 agonist and methods of using in the treatment of cognitive impairment |
-
2020
- 2020-12-18 MX MX2022007725A patent/MX2022007725A/es unknown
- 2020-12-18 CN CN202080096714.0A patent/CN115175911A/zh active Pending
- 2020-12-18 US US17/786,175 patent/US20230098667A1/en active Pending
- 2020-12-18 WO PCT/US2020/066182 patent/WO2021127543A1/en unknown
- 2020-12-18 JP JP2022537497A patent/JP2023507569A/ja active Pending
- 2020-12-18 AU AU2020405233A patent/AU2020405233A1/en active Pending
- 2020-12-18 EP EP20904223.3A patent/EP4077333A4/en active Pending
- 2020-12-18 IL IL294031A patent/IL294031A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4077333A1 (en) | 2022-10-26 |
| CN115175911A (zh) | 2022-10-11 |
| EP4077333A4 (en) | 2024-01-10 |
| JP2023507569A (ja) | 2023-02-24 |
| WO2021127543A1 (en) | 2021-06-24 |
| IL294031A (en) | 2022-08-01 |
| AU2020405233A1 (en) | 2022-07-14 |
| US20230098667A1 (en) | 2023-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013927A (es) | Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo. | |
| WO2018130868A8 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| MX2022007725A (es) | Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo. | |
| MX2016007808A (es) | Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro congnitivo. | |
| MX2020013374A (es) | Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo. | |
| EA201390710A1 (ru) | Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения | |
| GEP20207149B (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| AU2019268069A1 (en) | Methods and compositions for improving cognitive function | |
| MX2023000405A (es) | Combinaciones de agonistas del receptor a del acido gamma aminobutirico (gabaa) alfa 5 e inhibidores de la glicoproteina de vesicula sinaptica 2a (sv2a) y metodos de uso en el tratamiento del deterioro cognitivo. | |
| GEP20227446B (en) | New catecholamine prodrugs for use in treatment of parkinson's disease | |
| EA201390712A1 (ru) | Производные пиридазина, композиции и способы лечения когнитивного нарушения | |
| WO2009158467A3 (en) | Di-substituted phenyl compounds as phosphodiesterase 10 inhibitors | |
| JP2020186274A5 (es) | ||
| IL255782A (en) | Pharmacotherapeutic agents of levatiracetam with prolonged release | |
| PH12020551779A1 (en) | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | |
| MA43313B1 (fr) | Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation | |
| SA520420382B1 (ar) | مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1 | |
| IN2013DN11328A (es) | ||
| Fujioka et al. | Clinical presentation of a patient with SLC20A2 and THAP1 deletions: differential diagnosis of oromandibular dystonia | |
| MX2023000517A (es) | Polimorfos de un agonista del receptor a del acido gamma-aminobutirico (gabaa) alfa 5 y metodos de uso en el tratamiento del deterioro cognitivo. | |
| EA201691290A1 (ru) | Бензодиазепиновые производные, композиции и способы для лечения когнитивного нарушения | |
| Karaseva et al. | Synthesis of New 7-bromo-5-(2’-chlorophenyl)-3-arylamino-1, 2-dihydro-3 H-1, 4-benzodiazepine Derivatives and Their Influence on Appetite in Rats | |
| FI3541784T3 (fi) | Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina | |
| Smits et al. | The astrologist's posture: a useful clinical observation | |
| PH12019550251A1 (en) | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS |